CPRX FINANCIAL STATEMENTS

Catalyst Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

CPRXCatalyst Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue597 M $+11.7%

Gross Profit491.4 M $+6.7%

Operating Income267.6 M $+15.7%

EBITDA334.7 M $+13.0%

Net Income221.3 M $+12.1%

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CPRX	11.7%	82.3%	56.1%	37.1%
TLX	56.3%	50.8%	3.0%	-0.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CPRX	11.7%	82.3%	56.1%	37.1%
DYN	-100.0%	—	—	—
RCUS	67.4%	97.0%	-139.8%	-156.4%
TNGX	39.0%	97.3%	-184.5%	-188.2%
EWTX	-100.0%	—	—	—
VKTX	—	—	—	—
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity1 B $88%
Current Liabilities132.4 M $12%
Long-term Liabilities2.5 M $0%

Key Figures

YoY change

Total Assets1.1 B $+26.3%

Total Liabilities134.9 M $+17.7%

Total Equity1 B $+27.5%

Cash & ST Investments755.9 M $+30.2%

Total Debt2.7 M $-13.3%

Net Debt-753.2 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CPRX	7.10	0.3%	-2.25	88.2%
TLX	1.43	112.3%	13.13	35.1%
MSB	—	—	—	—
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CPRX	7.10	0.3%	-2.25	88.2%
DYN	19.92	2.2%	2.20	80.1%
RCUS	4.04	21.6%	2.15	52.6%
TNGX	27.38	8.4%	3.30	89.8%
EWTX	22.61	0.8%	2.82	95.1%
VKTX	5.72	—	—	82.5%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow208.2 M $-22.3%

Capital Expenditures85 K $-76.2%

Free Cash Flow208.1 M $-22.2%

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CPRX	34.9%	34.9%	0.0%	94.1%
TLX	-2.2%	-6.3%	4.1%	243.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CPRX	34.9%	34.9%	0.0%	94.1%
DYN	—	—	—	97.9%
RCUS	-206.8%	-207.2%	0.4%	132.2%
TNGX	-248.4%	-250.1%	1.8%	132.0%
EWTX	—	—	—	84.4%
VKTX	—	—	—	72.1%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on CPRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 8, 26. This content is for informational purposes only and is not investment advice.